Home › Cancer (all types) › Iowa
Cancer (all types) clinical trials in Iowa
17 studies for Cancer (all types) are looking for participants at sites in Iowa.
Cities in Iowa
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Iowa Health, Iowa City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- The State University of Iowa, Iowa City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- University of Iowa Hospitals ( Site 4017), Iowa City
RecruitingPhase 1/2
1 Month – 17 Years · All sexes · Updated Sep 25, 2026 · NCT07630974A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Holden Comprehensive Cancer Center, Iowa City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06901531Prospective Study to Assess a Diagnostic Aid for Cancer
- Iowa Clinic, West Des Moines
RecruitingObservational study
Ages 45 and older · All sexes · Updated Sep 21, 2026 · NCT07046260A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017), Iowa City
RecruitingPhase 1/2
1 Month – 17 Years · All sexes · Updated Sep 17, 2026 · NCT06941272Collection of Tissue Samples for Cancer Research
- University of Iowa, Iowa City
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198Lurbinectedin in FET-Fused Tumors
- University of Iowa Hospitals and Clinics, Iowa City
RecruitingPhase 1/2
Ages 10 and older · All sexes · Updated Sep 2, 2026 · NCT05918640Project: Every Child for Younger Patients With Cancer
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- Mercy Hospital, Cedar Rapids
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314A Study of ASP1002 in Adults for Treatment of Solid Tumors
- University of Iowa Hospitals, Iowa City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT05719558First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- University of Iowa, Iowa City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139Molecular Genetics Studies of Cancer Patients and Their Relatives
- Mercy Hospital, Cedar Rapids
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Jun 29, 2026 · NCT04185935A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Mission Cancer + Blood - Mission Cancer Foundation, Des Moines
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 24, 2026 · NCT06010329GEMINI-NSCLC: NSCLC Biomarker Study
- University of Iowa, Iowa City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT05236114Beat Childhood Cancer Specimen Banking and Data Registry
- University of Iowa, Iowa City
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Feb 3, 2026 · NCT04715178SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Iowa City
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.